Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

RTTNews | 125 dias atrás
Stocktwits
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

The European Commission is expected to announce a final decision in the coming months. FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL).

The positive CHMP opinion is supported by results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates and an acceptable safety profile of odronextamab in adults with R/R FL or R/R DLBCL. The EMA previously granted odronextamab Orphan Designation for both FL and DLBCL. Odronextamab is currently under clinical development and has not been approved by any regulatory authority.

Regeneron continues to evaluate the use of odronextamab as a monotherapy and in combination across earlier lines of therapy in challenging-to-treat lymphomas.

Marcadores : REGN
Stocktwits
read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 91 dias atrás
Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews | 272 dias atrás
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 853 dias atrás
Dollar Turns In Mixed Performance Ahead Of Jobs Data

Dollar Turns In Mixed Performance Ahead Of Jobs Data

The U.S. dollar recovered from early losses on Thursday after fairly encouraging economic data dashed hopes of any aggressive interest rate cut by the Federal Reserve next week, but gave up gains as the day progressed with investors awaiting non-farm payroll data due on Friday, and the presidential election next week.
RTTNews | 4h 41min atrás
Canadian Market Headed For Weak Close

Canadian Market Headed For Weak Close

Disappointing earnings updates from U.S. tech majors Microsoft Inc., and Meta Platforms, anxiety ahead of U.S. presidential election and the Federal Reserve's monetary policy meeting, and weak commodity prices are weighing on the Canadian market.
RTTNews | 6h 41min atrás
Swiss Market Ends Weak Again

Swiss Market Ends Weak Again

For the second consecutive day, the Switzerland market languished in red right through the day's session, as weak earnings updates from U.S. technology majors Microsoft Inc., and Meta Platforms, and weak euro zone inflation data hurt sentiment and sent stock prices drifting down south on Thursday.
RTTNews | 7h 31min atrás
Pound Falls After Autumn Statement

Pound Falls After Autumn Statement

The pound weakened against its major counterparts in the New York session on Thursday, following the announcement of the nation's latest budget, which included tax rises and big spending plans.
RTTNews | 7h 32min atrás
Ferramentas
Calendário Econômico
Market Hours
Interest Rates
Holidays Calendar
Mercado Forex
Volatilidade no Forex
Correlação no Forex
Notícias sobre Forex
forex analysis
Dados do COT
Liquidez
Calculadoras Forex
Mapa do Calor do Forex
Indicators Heatmap
Comunidade
Comunidade
Sistemas
Sistemas Mais Populares
Estratégias
Concursos
Gráficos de Forex
Sentimento do Forex
Indicador de Perspectivas
Análises
Corretoras
Prop Trading Firms
Serviços de VPS
Provedores de Sinais
Serviços de Programação de EA
Affiliate Programs
Serviços de Corretora PAMM
Serviços de Programa de Reembolso
Plataformas de Trading
Expert Advisors
Exchanges de Criptomoedas
Trading Courses
Corretoras
Spreads das Corretoras de Forex
Cotações de Corretoras de Forex
Swaps de Corretoras de Forex
Volume da Corretora de Forex
Promoções de Corretoras de Forex Broker News
Plataforma
Widgets
Recursos
API
RSS
Stock Portfolio
Affiliate Software
Gráficos Avançados
Assistência
Perguntas Frequentes
Ajuda
Entre em contato conosco
Relatar um erro!
Sobre
Blog
© 2024 Myfxbook Ltd. Todos os Direitos Reservados.
AVISO DE ALTO RISCO: A negociação no mercado de câmbio traz consigo um alto nível de risco que pode não ser adequado para qualquer investidor. A alavancagem cria exposição adicional a riscos e perdas. Antes de decidir negociar no mercado de câmbio, considere cuidadosamente seus objetivos de investimento, seu nível de experiência e sua tolerância ao risco. Você pode perder parte de seu investimento inicial ou todo ele. Não invista um dinheiro que você não tem condições de perder. Informe-se sobre os riscos associados à negociação no mercado de câmbio e procure o conselho de um consultor financeiro ou fiscal independente, caso tenha alguma dúvida. Quaisquer dados e informações são fornecidos "como estão" exclusivamente para fins informativos. Eles não se destinam a fins comerciais ou de aconselhamento. O desempenho passado não é indicativo de resultados futuros.